Show simple item record

dc.contributor.authorBraun, M S
dc.contributor.authorAdab, Fawzi
dc.contributor.authorBradley, C
dc.contributor.authorMcAdam, K
dc.contributor.authorThomas, G
dc.contributor.authorWadd, N J
dc.contributor.authorRea, D
dc.contributor.authorPhilips, R
dc.contributor.authorTwelves, C
dc.contributor.authorBozzino, J
dc.contributor.authorMacMillan, C
dc.contributor.authorSaunders, Mark P
dc.contributor.authorCounsell, R
dc.contributor.authorAnderson, Heather
dc.contributor.authorMcDonald, A
dc.contributor.authorStewart, J
dc.contributor.authorRobinson, A
dc.contributor.authorDavies, S
dc.contributor.authorRichards, F J
dc.contributor.authorSeymour, M T
dc.date.accessioned2009-08-27T09:11:30Z
dc.date.available2009-08-27T09:11:30Z
dc.date.issued2003-10-06
dc.identifier.citationModified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer. 2003, 89 (7):1155-8 Br. J. Canceren
dc.identifier.issn0007-0920
dc.identifier.pmid14520437
dc.identifier.doi10.1038/sj.bjc.6601237
dc.identifier.urihttp://hdl.handle.net/10541/78833
dc.description.abstractWe previously reported high activity for oxaliplatin and a modified de Gramont regimen (OxMdG) in a single centre study of patients with metastatic colorectal cancer. We now report results with a further 56 patients treated at 14 centres. Low rates of grade 3 and 4 toxicity were seen, with no toxic deaths. Objective response rates were CR/PR=53%; NC=34.7%; PD=12.2%. Median time to progression was 8.3 months and overall survival was 14.5 months. This regimen is more convenient than those based around the conventional de Gramont regimen but is highly active and well tolerated; it forms part of a current UK MRC phase 3 trial.
dc.language.isoenen
dc.subjectColorectal Canceren
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshColorectal Neoplasms
dc.subject.meshDisease Progression
dc.subject.meshFemale
dc.subject.meshFluorouracil
dc.subject.meshHumans
dc.subject.meshLeucovorin
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshOrganoplatinum Compounds
dc.subject.meshProspective Studies
dc.subject.meshSurvival Rate
dc.subject.meshTime Factors
dc.titleModified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer.en
dc.typeArticleen
dc.contributor.departmentCancer Research UK Centre in Leeds, Cookridge Hospital, Leeds LS16 6QB, UK.en
dc.identifier.journalBritish Journal of Canceren
html.description.abstractWe previously reported high activity for oxaliplatin and a modified de Gramont regimen (OxMdG) in a single centre study of patients with metastatic colorectal cancer. We now report results with a further 56 patients treated at 14 centres. Low rates of grade 3 and 4 toxicity were seen, with no toxic deaths. Objective response rates were CR/PR=53%; NC=34.7%; PD=12.2%. Median time to progression was 8.3 months and overall survival was 14.5 months. This regimen is more convenient than those based around the conventional de Gramont regimen but is highly active and well tolerated; it forms part of a current UK MRC phase 3 trial.


This item appears in the following Collection(s)

Show simple item record